Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rectal NSAIDs With or Without PDS for Prevention of Post-ERCP Pancreatitis
NCT07117318Recruiting
- Sponsor
- Air Force Medical University
- Start
- Jul 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of meloxicam in post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP) (2 arms), sponsored by Air Force Medical University. Primary endpoint: Rate of post-ERCP Pancreatitis at 30 days. Started Jul 2025; status: recruiting.
02
Drugs
meloxicam
03
Conditions
post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP)
Beyond the preview
Go deeper on NCT07117318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07117318.